We are reporting a randomized study comparing fludarabine in combination with busulfan (FB) or thiotepa (FT), as conditioning regimen for hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis. The primary study endpoint was progression-free survival (PFS). Sixty patients were enrolled with a median age of 56 years and an intermediate-2 or high-risk score in 65%, according to the Dynamic International Prognostic Staging System (DIPSS). Donors were HLA-identical sibling (n=25), matched unrelated (n=25) or single allele mismatched unrelated (n=10). With a median follow-up of 22 months (range 1-68), the following outcomes at 2 years after HSCT in the FB vs. the FT arm were as follows: PFS 43% vs 55%, (P=.28), overall survival (OS) 54% vs. 70% (P=.17), relapse/progression 36% vs 24% (P=.24), non-relapse mortality (NRM) 21% in both arms (P=.99) and graft failure 14% vs. 10% (P=.96). A better PFS was observed in patients with intermediate-1 DIPSS score (P=.03). Neutrophil and platelet engraftment was significantly influenced by prior splenectomy [HR 2.28 (95% CI, 1.16-4.51) P=.02] and splenomegaly at transplant [HR 0.51 (95% CI, 0.27-0.94) P=.03]. In conclusion, the clinical outcome after HSCT was comparable when using either a busulfan or thiotepa based conditioning regimen.

Busulfan or thiotepa based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group / F. Patriarca, A. Masciulli, A. Bacigalupo, S. Bregante, C. Pavoni, M.C. Finazzi, A. Bosi, D. Russo, F. Narni, G. Messina, E.P. Alessandrino, A.M. Carella, G. Milone, B. Bruno, S. Mammoliti, B. Bruno, R. Fanin, F. Bonifazi, A. Rambaldi. - In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. - ISSN 1083-8791. - (2019). [Epub ahead of print] [10.1016/j.bbmt.2018.12.064]

Busulfan or thiotepa based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group

M.C. Finazzi;A. Rambaldi
Ultimo
Writing – Review & Editing
2019

Abstract

We are reporting a randomized study comparing fludarabine in combination with busulfan (FB) or thiotepa (FT), as conditioning regimen for hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis. The primary study endpoint was progression-free survival (PFS). Sixty patients were enrolled with a median age of 56 years and an intermediate-2 or high-risk score in 65%, according to the Dynamic International Prognostic Staging System (DIPSS). Donors were HLA-identical sibling (n=25), matched unrelated (n=25) or single allele mismatched unrelated (n=10). With a median follow-up of 22 months (range 1-68), the following outcomes at 2 years after HSCT in the FB vs. the FT arm were as follows: PFS 43% vs 55%, (P=.28), overall survival (OS) 54% vs. 70% (P=.17), relapse/progression 36% vs 24% (P=.24), non-relapse mortality (NRM) 21% in both arms (P=.99) and graft failure 14% vs. 10% (P=.96). A better PFS was observed in patients with intermediate-1 DIPSS score (P=.03). Neutrophil and platelet engraftment was significantly influenced by prior splenectomy [HR 2.28 (95% CI, 1.16-4.51) P=.02] and splenomegaly at transplant [HR 0.51 (95% CI, 0.27-0.94) P=.03]. In conclusion, the clinical outcome after HSCT was comparable when using either a busulfan or thiotepa based conditioning regimen.
Myelofibrosis; allogeneic stem cell transplantation; busulfan; reduced intensity conditioning regimens; thiotepa
Settore MED/15 - Malattie del Sangue
20-dic-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1083879118308863-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.16 MB
Formato Adobe PDF
1.16 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/609916
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact